PharmaTelevision - AstraZeneca: Shaun Grady discusses AZ’s partnering strategy at BPE

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: AstraZeneca: Shaun Grady discusses AZ’s partnering strategy at BPE

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Paul Larsmon talks to Shaun Grady, VP Strategic Partnering Business Development of Astra Zeneca.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Shaun Grady's Role as Vice President of business development and strategy planning

Paul Larsmon :

Hello and welcome to PharmaTelevision News Review coming to you from a BioPartnering Europe 2011. With me is Shaun Grady, from AstraZeneca. Shaun, you are called the Vice President, Strategic Partnering and Business Development, tell me a little bit about what you do?

Shaun Grady:

So in AstraZeneca we've got a very strong focus on what we call externalization so acquisitions, licensing, partnering, and collaboration. We've set ourselves a target that 40% of our pipeline and portfolio will M&A through externalization from outside the company and then my role is Head of Business Development and Strategic Partnering, I run a group of about 120 people around the globe very much organized around our therapy areas, we have five small molecule therapy areas that we call innovative medicine units and within through that group we coordinate and lead the identification, evaluation and then execution of the business development transaction so acquisitions, licensing and partnering.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Paul Larsmon

Paul Larsmon has worked as a broadcast television journalist for 25 years, covering general news, business and politics. He has been both presenter and producer in several news broadcasters, including the major British television news company ITN. He joined PharmaTelevision as Executive Producer earlier this year and has been responsible for getting , PTV News launched.

Shaun Grady

Shaun Grady is presently VP Strategic Partnering and Business Development of AstraZeneca. Shaun Grady has global responsibility for the Strategic Partnering and Business Development (SPBD) function, dedicated to broadening AstraZeneca's access to scientific innovation outside our own laboratories - a key strategic priority for AstraZeneca. The scope of his team includes in-licensing, acquisition and partnering activities from early stage Discovery through to on-market commercial opportunities. Shaun originally joined ICI as an attorney and held positions in the Pharmaceuticals, Petrochemicals, and Head Office Legal Departments. Upon the demerger of Zeneca from ICI he was appointed Assistant General Counsel, Corporate. He worked on the merger of Astra and Zeneca, the merger of Zeneca Agrochemicals with Novartis Agribusiness to form Syngenta, and the creation of Avecia.

PharmaVentures

PharmaVentures is a company that has proven success in deals and alliances. PharmaVentures offers: Over 18 years of healthcare industry experience gained from working with in excess of 1000 clients in 38 countries, and conducting more than 450 assignments Over 40 specialist advisors, analysts and researchers Skills honed in many countries - 80% of its business comes from outside the UK.

AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal , cardiovascular, neuroscience , respiratory and inflammation , oncology and infectious disease . AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.